| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | Stephen M Hewitt | |
| Mei Li M Kwong | |||
| Li Jia | |||
| William C Faquin | |||
| James C Yang | |||
| Richard M Sherry | |||
| Jared J Gartner | |||
| Christian S Hinrichs | |||
| Sanja Stevanović | |||
| Stacey L Doran | |||
| Sabina Adhikary | |||
| P2860 | cites work | What is the appropriate approach to treating women with incurable cervical cancer? | Q38088946 |
| Chimeric antigen receptor T-cell therapies for lymphoma | Q38600697 | ||
| Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells | Q39122553 | ||
| Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy | Q39130451 | ||
| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial | Q40186710 | ||
| PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. | Q42363154 | ||
| Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution | Q47150991 | ||
| Genetic mechanisms of immune evasion in colorectal cancer | Q50420634 | ||
| Cancer immunotherapy using checkpoint blockade. | Q52641912 | ||
| Human papillomavirus and cervical cancer | Q58279986 | ||
| Chimeric antigen receptor-modified T cells: CD19 and the road beyond | Q88573551 | ||
| Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen | Q24623215 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion | Q27860475 | ||
| Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 | Q29616128 | ||
| T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. | Q30832820 | ||
| HPV-associated head and neck cancer: a virus-related cancer epidemic | Q34114152 | ||
| T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. | Q34621730 | ||
| Reassessing target antigens for adoptive T-cell therapy | Q34789569 | ||
| Development of therapeutic HPV vaccines | Q34953499 | ||
| Clinician's guide to human papillomavirus immunology: knowns and unknowns | Q34982885 | ||
| Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. | Q35943671 | ||
| Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6 | Q36154471 | ||
| Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy | Q36637039 | ||
| A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors | Q36709308 | ||
| Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy | Q36928580 | ||
| Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. | Q37095348 | ||
| Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma | Q37222679 | ||
| P433 | issue | 30 | |
| P304 | page(s) | 2759-2768 | |
| P577 | publication date | 2019-08-13 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study | |
| P478 | volume | 37 |
| Q90127107 | Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors |
| Q99575160 | Second line salvage systemic therapy for advanced penile cancer |
| Q97870313 | Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers |
| Q100315218 | The Anticancer Potential of T Cell Receptor-Engineered T Cells |
| Q97432032 | Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells |
Search more.